A study evaluating CAM2058 for the prevention and treatment of postoperative pain, nausea and vomiting.
Phase of Trial: Phase I
Latest Information Update: 09 Nov 2016
At a glance
- Drugs Buprenorphine/granisetron (Primary)
- Indications Postoperative nausea and vomiting; Postoperative pain
- Focus Adverse reactions
- 09 Nov 2016 New trial record
- 24 Oct 2016 According to a Braeburn Pharmaceuticals media release, company is planning clinical development of CAM2058 during the fourth quarter of 2016.